Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

GenNext Technologies Introduces Protein Footprinting Products to Japan through Kiko Tech Co., LTD.

Latest Posts

Abraham Verghese MD Appointed to the Board of Directors of Athos Therapeutics

"Abraham Verghese MD is a highly distinguished physician, humanist, administrator, and adviser," said Allan Pantuck, MD, MS, FACS, Chairman & CMO.

University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder

The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug-using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the FDA.

BRIM Biotechnology & Ora Announce New Partnership

BRIM Biotechnolgy notes the new partnership builds on the success of our previous collaboration for Phase 2 trials and will help to speed the progression of BRM421 through late-stage clinical development toward regulatory filing.

Cytel Designed & Led TOGETHER Trial Wins Society of Clinical Trial’s David Sackett Trial of the Year Award

TOGETHER trial has enrolled over 6000 patients in 22 research sites in Brazil.  It is now expanding to Pakistan and South Africa, Rwanda, DRC, and Vietnam.

GenNext Technologies, Inc. (GenNext), announced today a partnership with Kiko Tech Co., Ltd., to provide Flash Oxidation (Fox™) Protein Footprinting Systems to the Japanese life science research market.

Under an agreement between the parties, Kiko Tech has been appointed sole distributor for the GenNext product portfolio for Japan. Together, GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation (Fox™) Protein Footprinting Systems.

Kiko Tech is a premier distributor of state-of-the-art instruments and reagents for molecular diagnostics, proteomics, applied testing, pharmaceutical, and academic research since its establishment in 1974. The Kiko Tech team is excited about the opportunity to introduce the Japanese scientific community to the novel Fox™-based approach to Hydroxyl Radical Protein Footprinting (HRPF).

GenNext introduced Fox-Based HRPF to the market as a disruptive, intrinsically scalable approach to protein Higher Order Structure (HOS) analysis to increase the effectiveness and minimize adverse drug reactions of biopharmaceuticals. This protein footprinting method, originally demonstrated in a 2021 Journal of the American Society of Mass Spectrometry paper, is experiencing rapid adoption in North America and Europe by leading biopharmaceutical companies.

A GenNext HRPF study can address scientific questions that previously required difficult, expensive, and time-consuming hydrogen deuterium exchange, nuclear magnetic resonance, X-ray crystallography or cryo-electron microscopy experiments. Alternatively, researchers would have to combine multiple techniques such as circular dichroism spectroscopy, size-exclusion chromatography, and light-scattering analysis to generate less informative results than by conducting a single series of GenNext HRPF experiments.

“The GenNext team is very pleased to collaborate with Kiko Tech to introduce our products to Japan as part of our global expansion program,” said Scot R. Weinberger, CEO and Founder of GenNext. He continued, “We anticipate that Japanese biopharmaceutical researchers will be receptive to and adopt HRPF as a new standard to elucidate HOS, and we have found the perfect partner in Kiko Tech who are already active in this area.”

“Kiko Tech is excited to bring GenNext Technologies products to the Japanese life science community,” said Shigenobu Fukushima, General Manager of Kiko Tech. “GenNext’s products move HOS beyond the limitations inherent in current techniques, enabling our customers to discover and develop biopharmaceuticals faster and with higher quality.”

In the USA, GenNext Technologies will be presenting the capabilities of its platform at the upcoming American Society of Mass Spectrometry meeting (June 5-9, 2022).  At the same time, Japanese researchers will be able to learn about the HRPF technique and GenNext products at the Japanese Society of Protein Sciences meeting.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine